MedCity News
AUGUST 27, 2023
Researchers at the University of Texas MD Anderson Cancer Center published two studies this week on a new approach that could improve treatment for patients with pancreatic cancer. The preclinical studies showed that combining immunotherapy with a KRAS inhibitor can lead to long-lasting tumor elimination.
Copyright Clearance Center
AUGUST 27, 2023
“Good name in man and woman,” wrote Shakespeare, “is the immediate jewel of their souls.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
AUGUST 27, 2023
A new study found that between 16.2% and 17.7% of Medicare Advantage enrollees reported using post-acute care services, compared to 22.4% to 24.1% of traditional Medicare enrollees.
Pharmaceutical Technology
AUGUST 27, 2023
Selinexor is under clinical development by Karyopharm Therapeutics and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis).
MedCity News
AUGUST 27, 2023
As nursing remains the most trusted profession and NPs have long been accepted as primary care providers, nurses and NPs are uniquely qualified to guide patients through care interactions and bring the consistency associated with primary care to new places.
Pharmaceutical Technology
AUGUST 27, 2023
Patidistrogene bexoparvovec is a gene therapy commercialized by Sarepta Therapeutics, with a leading Phase II program in Limb-Girdle Muscular Dystrophy.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
AUGUST 27, 2023
Selinexor is under clinical development by Karyopharm Therapeutics and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis).
MedCity News
AUGUST 27, 2023
The Walt Disney Company excels in designing exceptional service because they are hyper-focused on listening, tracking, designing, and measuring the experiences of guests visiting their properties. We can apply this approach in pharma by enhancing our patient journey maps and go beyond focusing on the key clinical engagement touch points (e.g., doctor visits, prescription pickups) and enriching our insights with the micro-moments surrounding these obvious events.
PharmaTech
AUGUST 27, 2023
Speed is a critical factor in early-stage development. Solid state studies within an integrated CMC platform can support formulation development, accelerate timelines to phase 1 clinical studies and increase the likelihood of successful clinical trial results.
Pharmaceutical Technology
AUGUST 27, 2023
Following public outcry and a government investigation, Allina Health has reneged on their policy barring debtors from out-patient care.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaTech
AUGUST 27, 2023
Webinar Date/Time: Wed, Sep 20, 2023 11:00 AM EDT
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.
Pharmaceutical Technology
AUGUST 27, 2023
Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration).
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
AUGUST 27, 2023
Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration).
Pharmaceutical Technology
AUGUST 27, 2023
Zanidatamab is a monoclonal antibody commercialized by Jazz Pharmaceuticals, with a leading Phase III program in Adenocarcinoma Of The Gastroesophageal Junction.
Pharmaceutical Technology
AUGUST 27, 2023
Quisovalimab is a monoclonal antibody commercialized by Avalo Therapeutics, with a leading Phase II program in Crohn's Disease (Regional Enteritis).
Pharmaceutical Technology
AUGUST 27, 2023
Lutetium (lu177) lilotomab satetraxetan is under clinical development by Thor Medical and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
AUGUST 27, 2023
Lutetium (lu177) lilotomab satetraxetan is under clinical development by Thor Medical and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia.
Pharmaceutical Technology
AUGUST 27, 2023
Linavonkibart is a monoclonal antibody commercialized by Scholar Rock Holding, with a leading Phase I program in Non-Small Cell Lung Cancer.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Gastric Ulcers.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer.
Pharmaceutical Technology
AUGUST 27, 2023
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Gastric Ulcers.
Expert insights. Personalized for you.
96 
Let's personalize your content